AI-generated analysis. Always verify with the original filing.
Moleculin Biotech, Inc. disclosed preliminary blinded data from its Phase 2B/3 MIRACLE trial of Annamycin plus cytarabine in R/R AML, reporting a 40% CRc rate (30% CR, 10% CRh) in the first 30 subjects, with 35 subjects treated as of February 10, 2026, and on track for first unblinding after treating 45 subjects in Q1 2026. The Company highlighted a 67% improvement over historical cytarabine CR rates and absence of cardiotoxicity.
Event Type
Disclosure
Voluntary
Variant
8-K
of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be “filed” for the purpose of the Securities Exchange Act of 1934,
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated February 18, 2026 104 Cover page Interactive Data File (format